Status:
COMPLETED
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
Lead Sponsor:
Alexion Pharmaceuticals, Inc.
Collaborating Sponsors:
Achillion, a wholly owned subsidiary of Alexion
Conditions:
Human Immunodeficiency Virus (HIV)-1 Infection
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and me...
Detailed Description
This study is an open-label extension study for participants who have completed 14 days of treatment in Study ACH443-014A and meet all inclusion and exclusion criteria. Elvucitabine treatment (10 mg) ...
Eligibility Criteria
Inclusion
- Participants who have completed 14 days of treatment in Study ACH443-014A and who, in the Investigator's judgment, remain candidates to receive elvucitabine together with background ART.
Exclusion
- Failure to meet inclusion criteria
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00380159
Start Date
September 1 2006
End Date
January 1 2009
Last Update
August 14 2023
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Site
Atlanta, Georgia, United States, 30308
2
Clinical Trial Site
Cincinnati, Ohio, United States, 45242
3
Clinical Trial Site
Santo Domingo, Dominican Republic
4
Clinical Trial Site
Berlin, Germany